Kewaunee Scientific Appoints Interim CFO

Ticker: KEQU · Form: 8-K · Filed: Mar 22, 2024 · CIK: 55529

Kewaunee Scientific CORP /De/ 8-K Filing Summary
FieldDetail
CompanyKewaunee Scientific CORP /De/ (KEQU)
Form Type8-K
Filed DateMar 22, 2024
Risk Levelmedium
Pages2
Reading Time2 min
Key Dollar Amounts$2.50, $250,000
Sentimentneutral

Sentiment: neutral

Topics: management-change, executive-appointment, cfo

TL;DR

Kewaunee Scientific names David Dykeman interim CFO at $225k/year, he keeps his board seat.

AI Summary

Kewaunee Scientific Corporation announced on March 18, 2024, the appointment of David L. Dykeman as Interim Chief Financial Officer, effective immediately. Dykeman, who has served on the Board of Directors since 2021, will also continue his director duties. He will receive an annual salary of $225,000 for his CFO role, in addition to his director compensation.

Why It Matters

The company has appointed an interim CFO, indicating a potential leadership transition or ongoing search for a permanent executive, which could impact financial strategy and investor confidence.

Risk Assessment

Risk Level: medium — The appointment of an interim CFO can signal instability or a transition period within the company's financial leadership, which warrants closer monitoring.

Key Numbers

Key Players & Entities

FAQ

Who has been appointed as the Interim Chief Financial Officer?

David L. Dykeman has been appointed as the Interim Chief Financial Officer.

When was the appointment effective?

The appointment was effective immediately as of March 18, 2024.

What is the annual salary for the Interim CFO position?

The annual salary for the Interim CFO position is $225,000.

Will David L. Dykeman continue his role as a Director?

Yes, David L. Dykeman will continue to serve on the Board of Directors.

What other compensation does David L. Dykeman receive?

In addition to his Interim CFO salary, David L. Dykeman will continue to receive his director compensation.

Filing Stats: 613 words · 2 min read · ~2 pages · Grade level 10.3 · Accepted 2024-03-22 16:16:00

Key Financial Figures

Filing Documents

Financial Statements and Exhibits

Financial Statements and Exhibits (d) Exhibits: Exhibit No. 10.1 Retention Bonus Agreement, dated March 18, 2024, by and between Kewaunee Scientific Corporation and Thomas D. Hull III. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). Signature Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. (Registrant) Kewaunee Scientific Corporation Date: March 22, 2024 /s/ Donald T. Gardner III Donald T. Gardner III Vice President, Finance and Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing